Myelodysplastic Syndrome – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, Myelodysplastic Syndrome - Pipeline Review, H1 2012, provides an overview of the Myelodysplastic Syndrome therapeutic pipeline. This report provides information on the therapeutic development for Myelodysplastic Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Myelodysplastic Syndrome. Myelodysplastic Syndrome - Pipeline Review, H1 2012 is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Myelodysplastic Syndrome.
- A review of the Myelodysplastic Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Myelodysplastic Syndrome pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Myelodysplastic Syndrome.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Myelodysplastic Syndrome pipeline depth and focus of Myelodysplastic Syndrome therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables 6
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Myelodysplastic Syndrome Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for Myelodysplastic Syndrome 12
Myelodysplastic Syndrome Therapeutics under Development by Companies 14
Myelodysplastic Syndrome Therapeutics under Investigation by Universities/Institutes 18
Late Stage Products 28
Comparative Analysis 28
Mid Clinical Stage Products 29
Comparative Analysis 29
Early Clinical Stage Products 30
Comparative Analysis 30
Pre-Clinical Stage Products 31
Comparative Analysis 31
Myelodysplastic Syndrome Therapeutics – Products under Development by Companies 32
Myelodysplastic Syndrome Therapeutics – Products under Investigation by Universities/Institutes 36
Companies Involved in Myelodysplastic Syndrome Therapeutics Development 67
Genzyme Corporation 67
Johnson & Johnson 68
Kyowa Hakko Kirin Co., Ltd. 69
Abbott Laboratories 70
Amgen Inc. 71
Sanofi-Aventis 72
medac GmbH 73
Merck & Co., Inc. 74
Dainippon Sumitomo Pharma Co., Ltd. 75
Gamida Cell Ltd. 76
Bio-Path Holdings, Inc. 77
Aldagen, Inc. 78
Millennium Pharmaceuticals, Inc. 79
Novartis AG 80
BioMarin Pharmaceutical Inc. 81
Cephalon, Inc. 82
Nippon Shinyaku Co., Ltd. 83
Sunesis Pharmaceuticals, Inc. 84
SuperGen, Inc. 85
Cyclacel Pharmaceuticals Inc. 86
Celgene Corporation 87
Incyte Corporation 88
Access Pharmaceuticals, Inc. 89
4SC AG 90
Lorus Therapeutics Inc 91
MethylGene Inc 92
OXiGENE, Inc. 93
Telik, Inc. 94
TopoTarget A/S 95
Array BioPharma Inc. 96
Threshold Pharmaceuticals, Inc. 97
Synta Pharmaceuticals Corp. 98
BioAlliance Pharma SA 99
Clavis Pharma ASA 100
Cellerant Therapeutics, Inc. 101
Chroma Therapeutics Ltd. 102
BioMAS Ltd. 103
S*BIO Pte Ltd 104
Stemline Therapeutics, Inc. 105
Onconova Therapeutics, Inc 106
Syndax Pharmaceuticals, Inc. 107
Concert Pharmaceuticals, Inc. 108
KaloBios Pharmaceuticals, Inc. 109
Aprea AB. 110
Targa Therapeutics Corp. 111
Myelodysplastic Syndrome – Therapeutics Assessment 112
Assessment by Monotherapy Products 112
Assessment by Combination Products 113
Assessment by Route of Administration 114
Assessment by Molecule Type 116
Drug Profiles 119
StemEx - Drug Profile 119
Vosaroxin - Drug Profile 121
Estybon - Drug Profile 123
NS-17 - Drug Profile 125
Revlimid + Procrit - Drug Profile 126
Vosaroxin + Cytarabine - Drug Profile 127
Prograf + Methotrexate - Drug Profile 129
Vidaza - Drug Profile 130
Busulfan + Cyclophosphamide - Drug Profile 131
Fludarabine Phosphate + Melphalan - Drug Profile 132
Cyclophosphamide + Etoposide + Total Body Irradiation - Drug Profile 133
Carboplatin + Thiotepa + Cyclophosphamide - Drug Profile 134
Amsacrine + Asparaginase + Cytarabine + Daunorubicin + Etoposide + Methotrexate + Mitoxantrone + Hydrocortisone - Drug Profile 135
Thymoglobulin - Drug Profile 138
Campath - Drug Profile 139
Fludarabine Phosphate + Anti-Thymocyte Globulin - Drug Profile 140
Cyclosporine + Anti-thymocyte globulin - Drug Profile 141
Vidaza - Drug Profile 142
Fludarabine Phosphate - Drug Profile 144
Ondansetron - Drug Profile 145
Treosulfan - Drug Profile 146
Revlimid - Drug Profile 147
Busulfan + Fludarabine + Cyclophosphamide + Radiation Therapy + Transplantation - Drug Profile 149
Asparaginase + Cytarabine + Daunorubicin + Etoposide + Thioguanine - Drug Profile 150
Epoetin Alfa + Filgrastim - Drug Profile 152
Cytarabine + Etoposide + Idarubicin - Drug Profile 153
Aldesleukin + Filgrastim + Asparaginase + Busulfan + Cyclophosphamide + Cytarabine + Daunorubicin Hydrochloride + Dexamethasone + Etoposide + Fludarabine Phosphate + Idarubicin + Methotrexate + Therapeutic Hydrocortisone + Thioguanine + Allogeneic Bone Marrow Transplantation + Radiation Therapy - Drug Profile 155
Anti-Thymocyte Globulin + Cyclosporine - Drug Profile 159
Deferasirox - Drug Profile 160
Cytarabine + Mitoxantrone Hydrochloride + Etoposide - Drug Profile 161
Idarubicin + Cytarabine + Daunorubicin Hydrochloride + Dexamethasone + Etoposide + Thioguanine + Radiation Therapy - Drug Profile 163
Mitoxantrone Hydrochloride + Cytarabine + Daunorubicin Hydrochloride + Dexamethasone + Etoposide + Thioguanine + Radiation Therapy - Drug Profile 165
Decitabine - Drug Profile 167
Idarubicin + Cyclophosphamide + Busulfan + Melphalan + Radiation Therapy + Stem Cell Transplantation - Drug Profile 168
Busulfan + Cyclophosphamide + Melphalan + Allogeneic Hematopoietic Cell Transplantation - Drug Profile 170
Cyclophosphamide + Cyclosporine + Methotrexate + Stem Cell Transplantation + Radiation Therapy - Drug Profile 171
Busulfan + Radiation Therapy + Stem Cell Transplantation - Drug Profile 173
Tacrolimus + Sirolimus - Drug Profile 175
Umbilical Cord Blood Transplantation - Drug Profile 176
bone marrow transplantation + T cell-depleted bone marrow transplantation - Drug Profile 178
Alemtuzumab + Arsenic Trioxide + Azacitidine + Busulfan + Clofarabine + Cytarabine + Daunorubicin Hydrochloride + Fludarabine Phosphate + Gemtuzumab Ozogamicin + Melphalan + Tipifarnib + Allogeneic Hematopoietic Stem Cell Transplantation - Drug Profile 179
Bone Marrow Transplantation - Drug Profile 182
Cytarabine + Daunorubicin + Etoposide + Hydroxyurea + Idarubicin + Mitoxantrone + Thioguanine + Tretinoin + Valspodar - Drug Profile 183
5-Azacytidin - Drug Profile 186
Cyclophosphamide + Total Body Irradiation - Drug Profile 187
Cyclosporine + Methotrexate - Drug Profile 189
Fludarabine + Busulfan + Cyclophosphamide + Radiation Therapy + Allogeneic Stem Cell Transplantation - Drug Profile 191
Myelodysplastic Syndrome Therapeutics – Drug Profile Updates 193
Myelodysplastic Syndrome Therapeutics – Discontinued Products 200
Myelodysplastic Syndrome Therapeutics - Dormant Products 204
Myelodysplastic Syndrome – Product Development Milestones 216
Featured News & Press Releases 216
Appendix 225
Methodology 225
Expert Panel Validation 226
Contact Us 226
Disclaimer 226

List of Tables

Number of Products Under Development for Myelodysplastic Syndrome, H1 2012 15
Products under Development for Myelodysplastic Syndrome – Comparative Analysis, H1 2012 16
Number of Products under Development by Companies, H1 2012 18
Number of Products under Development by Companies, H1 2012 (Contd..1) 19
Number of Products under Development by Companies, H1 2012 (Contd..2) 20
Number of Products under Investigation by Universities/Institutes, H1 2012 22
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 23
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 24
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 25
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 26
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 27
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 28
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..7) 29
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..8) 30
Comparative Analysis by Late Stage Development, H1 2012 31
Comparative Analysis by Mid Clinical Stage Development, H1 2012 32
Comparative Analysis by Early Clinical Stage Development, H1 2012 33
Comparative Analysis by Pre-Clinical Stage Development, H1 2012 34
Products under Development by Companies, H1 2012 35
Products under Development by Companies, H1 2012 (Contd..1) 36
Products under Development by Companies, H1 2012 (Contd..2) 37
Products under Development by Companies, H1 2012 (Contd..3) 38
Products under Investigation by Universities/Institutes, H1 2012 39
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 40
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 41
Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 42
Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 43
Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 44
Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 45
Products under Investigation by Universities/Institutes, H1 2012 (Contd..7) 46
Products under Investigation by Universities/Institutes, H1 2012 (Contd..8) 47
Products under Investigation by Universities/Institutes, H1 2012 (Contd..9) 48
Products under Investigation by Universities/Institutes, H1 2012 (Contd..10) 49
Products under Investigation by Universities/Institutes, H1 2012 (Contd..11) 50
Products under Investigation by Universities/Institutes, H1 2012 (Contd..12) 51
Products under Investigation by Universities/Institutes, H1 2012 (Contd..13) 52
Products under Investigation by Universities/Institutes, H1 2012 (Contd..14) 53
Products under Investigation by Universities/Institutes, H1 2012 (Contd..15) 54
Products under Investigation by Universities/Institutes, H1 2012 (Contd..16) 55
Products under Investigation by Universities/Institutes, H1 2012 (Contd..17) 56
Products under Investigation by Universities/Institutes, H1 2012 (Contd..18) 57
Products under Investigation by Universities/Institutes, H1 2012 (Contd..19) 58
Products under Investigation by Universities/Institutes, H1 2012 (Contd..20) 59
Products under Investigation by Universities/Institutes, H1 2012 (Contd..21) 60
Products under Investigation by Universities/Institutes, H1 2012 (Contd..22) 61
Products under Investigation by Universities/Institutes, H1 2012 (Contd..23) 62
Products under Investigation by Universities/Institutes, H1 2012 (Contd..24) 63
Products under Investigation by Universities/Institutes, H1 2012 (Contd..25) 64
Products under Investigation by Universities/Institutes, H1 2012 (Contd..26) 65
Products under Investigation by Universities/Institutes, H1 2012 (Contd..27) 66
Products under Investigation by Universities/Institutes, H1 2012 (Contd..28) 67
Products under Investigation by Universities/Institutes, H1 2012 (Contd..29) 68
Products under Investigation by Universities/Institutes, H1 2012 (Contd..30) 69
Genzyme Corporation, H1 2012 70
Johnson & Johnson, H1 2012 71
Kyowa Hakko Kirin Co., Ltd., H1 2012 72
Abbott Laboratories, H1 2012 73
Amgen Inc., H1 2012 74
Sanofi-Aventis, H1 2012 75
medac GmbH, H1 2012 76
Merck & Co., Inc., H1 2012 77
Dainippon Sumitomo Pharma Co., Ltd., H1 2012 78
Gamida Cell Ltd., H1 2012 79
Bio-Path Holdings, Inc., H1 2012 80
Aldagen, Inc., H1 2012 81
Millennium Pharmaceuticals, Inc., H1 2012 82
Novartis AG, H1 2012 83
BioMarin Pharmaceutical Inc., H1 2012 84
Cephalon, Inc., H1 2012 85
Nippon Shinyaku Co., Ltd., H1 2012 86
Sunesis Pharmaceuticals, Inc., H1 2012 87
SuperGen, Inc., H1 2012 88
Cyclacel Pharmaceuticals Inc., H1 2012 89
Celgene Corporation, H1 2012 90
Incyte Corporation, H1 2012 91
Access Pharmaceuticals, Inc., H1 2012 92
4SC AG, H1 2012 93
Lorus Therapeutics Inc, H1 2012 94
MethylGene Inc, H1 2012 95
OXiGENE, Inc., H1 2012 96
Telik, Inc., H1 2012 97
TopoTarget A/S, H1 2012 98
Array BioPharma Inc., H1 2012 99
Threshold Pharmaceuticals, Inc., H1 2012 100
Synta Pharmaceuticals Corp., H1 2012 101
BioAlliance Pharma SA, H1 2012 102
Clavis Pharma ASA, H1 2012 103
Cellerant Therapeutics, Inc., H1 2012 104
Chroma Therapeutics Ltd., H1 2012 105
BioMAS Ltd., H1 2012 106
S*BIO Pte Ltd, H1 2012 107
Stemline Therapeutics, Inc., H1 2012 108
Onconova Therapeutics, Inc, H1 2012 109
Syndax Pharmaceuticals, Inc., H1 2012 110
Concert Pharmaceuticals, Inc., H1 2012 111
KaloBios Pharmaceuticals, Inc., H1 2012 112
Aprea AB., H1 2012 113
Targa Therapeutics Corp., H1 2012 114
Assessment by Monotherapy Products, H1 2012 115
Assessment by Combination Products, H1 2012 116
Assessment by Stage and Route of Administration, H1 2012 118
Assessment by Molecule Type, H1 2012 121
Myelodysplastic Syndrome Therapeutics – Drug Profile Updates 196
Myelodysplastic Syndrome Therapeutics – Discontinued Products 203
Myelodysplastic Syndrome Therapeutics – Discontinued Products (Contd..1) 204
Myelodysplastic Syndrome Therapeutics – Discontinued Products (Contd..2) 205
Myelodysplastic Syndrome Therapeutics – Discontinued Products (Contd..3) 206
Myelodysplastic Syndrome Therapeutics – Dormant Products 207
Myelodysplastic Syndrome Therapeutics – Dormant Products (Contd..1) 208
Myelodysplastic Syndrome Therapeutics – Dormant Products (Contd..2) 209
Myelodysplastic Syndrome Therapeutics – Dormant Products (Contd..3) 210
Myelodysplastic Syndrome Therapeutics – Dormant Products (Contd..4) 211
Myelodysplastic Syndrome Therapeutics – Dormant Products (Contd..5) 212
Myelodysplastic Syndrome Therapeutics – Dormant Products (Contd..6) 213
Myelodysplastic Syndrome Therapeutics – Dormant Products (Contd..7) 214
Myelodysplastic Syndrome Therapeutics – Dormant Products (Contd..8) 215
Myelodysplastic Syndrome Therapeutics – Dormant Products (Contd..9) 216
Myelodysplastic Syndrome Therapeutics – Dormant Products (Contd..10) 217
Myelodysplastic Syndrome Therapeutics – Dormant Products (Contd..11) 218

List of Figures

Number of Products under Development for Myelodysplastic Syndrome, H1 2012 15
Products under Development for Myelodysplastic Syndrome – Comparative Analysis, H1 2012 16
Products under Development by Companies, H1 2012 17
Products under Investigation by Universities/Institutes, H1 2012 21
Late Stage Products, H1 2012 31
Mid Clinical Stage Products, H1 2012 32
Early Clinical Stage Products, H1 2012 33
Pre-Clinical Stage Products, H1 2012 34
Assessment by Monotherapy Products, H1 2012 115
Assessment by Combination Products, H1 2012 116
Assessment by Route of Administration, H1 2012 117
Assessment by Stage and Route of Administration, H1 2012 118
Assessment by Molecule Type, H1 2012 119
Assessment by Stage and Molecule Type, H1 2012 120